文献速递白血病

砷剂与化疗治疗急性早幼粒细胞白血病患者长期生活质量比较

Long-term quality of life of patients with acute promyelocytic leukemia treated with arsenic trioxide vs chemotherapy.
PubMed 文献 · Blood Adv · 2021-01-01

本研究基于APL0406随机对照试验的随访,比较ATRA联合砷剂与ATRA联合标准化疗治疗急性早幼粒细胞白血病(APL)患者的长期健康相关生活质量。共分析161例患者(砷剂组83例,化疗组78例),中位诊断后8年。砷剂组在角色功能、呼吸困难及SF-36躯体成分评分上显示临床意义的改善,周围神经病变和晚期合并症无差异。

要点

  • 中位随访8年,砷剂组角色功能(Δ=8.4)和呼吸困难(Δ=-8.5)优于化疗组。
  • 砷剂组SF-36躯体成分评分有临床相关改善(Δ=4.6),精神成分无差异。
  • 两组周围神经病变评分及晚期合并症发生率相似。

核心结论

  • ATRA-ATO方案更强且持久的抗白血病疗效与更好的长期患者报告结局相关。

研究设计与样本

  • 基于随机对照试验APL0406的随访研究,纳入既往入组患者,最终分析161例(ATRA-ATO组83例,ATRA化疗组78例),中位诊断后8年。

主要发现

  • EORTC QLQ-C30角色功能差异Δ=8.4(95%CI 0.5-16.3),呼吸困难差异Δ=-8.5(95%CI -16.4至-0.7),均利于ATRA-ATO组。
  • SF-36躯体成分评分差异Δ=4.6(95%CI 1.3-7.8),利于ATRA-ATO组;精神成分评分无临床相关差异。
  • EORTC QLQ-CIPN20各量表评分及晚期合并症患病率两组相似。

临床怎么用

  • 对于APL患者,ATRA-ATO方案不仅抗白血病疗效更优,还可带来更好的长期生活质量,支持其作为首选治疗。

局限性

  • 本研究为APL0406试验的随访分析,样本量有限(161例),可能影响结果的外推性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The main objective of this study was to compare the long-term health-related quality of life of patients with acute promyelocytic leukemia (APL) treated with all-trans retinoic acid (ATRA) plus arsenic trioxide (ATO) vs ATRA plus standard chemotherapy. Patients previously enrolled in the randomized controlled trial APL0406 were considered eligible for this follow-up study. The following patient-reported outcome measures were used: the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core30 (EORTC QLQ-C30), the EORTC Quality of Life Questionnaire Chemotherapy-Induced Peripheral Neuropathy 20 (QLQ-CIPN20), and the Short Form Health Survey 36 (SF-36). The prevalence of late comorbidities and health problems was also assessed. The clinical significance of differences was evaluated based on predefined thresholds. A total of 161 of 232 potentially eligible patients were analyzed, of whom 83 were treated with ATRA-ATO and 78 were treated with ATRA chemotherapy. The median time since diagnosis of the study sample was 8 years. The 2 largest clinically meaningful differences in the EORTC QLQ-C30 were observed for role functioning (Δ = 8.4; 95% confidence interval [CI], 0.5 to 16.3) and dyspnea (Δ = -8.5; 95% CI, -16.4 to -0.7), favoring patients treated with ATRA-ATO. With regard to the SF-36 results, a clinically relevant better physical component score (Δ = 4.6; 95% CI, 1.3 to 7.8) was observed in patients treated with ATRA-ATO, but this was not the case for the mental component score. The 2 groups showed similar profiles in the scores of the EORTC QLQ-CIPN20 scales and in the prevalence of late comorbidities. Overall, our findings suggest that the greater and more sustained antileukemic efficacy of ATRA-ATO is also associated with better long-term patient-reported outcomes than ATRA chemotherapy. This study was registered at www.clinicaltrials.gov as #NCT03096496.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Efficace F, Platzbecker U, Breccia M, et al. Long-term quality of life of patients with acute promyelocytic leukemia treated with arsenic trioxide vs chemotherapy. Blood Adv. 2021. PMID: 34529768. doi:10.1182/bloodadvances.2021004649

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。